House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Haematology

Thrombophilia testing

ASH · 2023 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

ASH’s 2023 thrombophilia-testing guideline asks whether testing changes a meaningful treatment or prevention decision. Most recommendations are conditional and based on very-low-certainty evidence, often modelled rather than directly tested. The trigger for VTE, planned anticoagulation duration, exact familial defect and degree of relationship all matter; testing is not a general substitute for clinical risk assessment.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Test only when a defined decision could change

  • Link thrombophilia testing to a specific management question: duration of anticoagulation, prevention during risk periods or hormone avoidance. Weigh thrombosis, bleeding, burden, cost and patient preference rather than ordering an indiscriminate panel. [1]
  • Interpret results with laboratory and clinical expertise. Acquired reductions in antithrombin, protein C or protein S, comorbidities, hormonal exposure and biological variation can mimic inherited deficiency. [1]
  • Do not infer thrombophilia from MTHFR variants or other unvalidated panel components. The guideline excludes MTHFR polymorphisms as unassociated with VTE and notes uncertain associations for several additional coagulation and fibrinolysis tests. [1]

Distinguish provoked and unprovoked VTE

  • After primary treatment of unprovoked VTE, ASH conditionally advises against thrombophilia testing to set anticoagulation duration. This assumes the treatment-guideline approach of indefinite therapy for most unprovoked events; a negative panel is not the proposed reason to stop. [1]
  • After surgery-provoked VTE and completed primary short-term treatment, ASH conditionally suggests no thrombophilia testing to decide treatment duration. [1]
  • After VTE from a nonsurgical major transient risk factor and completed primary treatment, ASH conditionally suggests testing: indefinite anticoagulation for thrombophilia and stopping for a negative result. This is a very-low-certainty strategy, not a universal rule for every provoked event. [1]
  • After pregnancy- or postpartum-provoked VTE and completed primary treatment, ASH conditionally suggests testing to guide duration, with indefinite anticoagulation when thrombophilia is present and stopping when absent. Evidence certainty is very low. [1]
  • After combined-oral-contraceptive-associated VTE and completed primary short-term treatment, ASH conditionally suggests testing, indefinite anticoagulation for thrombophilia and stopping for a negative result. The evidence is very uncertain. [1]
  • If the VTE has not been classified as provoked or unprovoked, do not use a thrombophilia panel as a substitute. ASH suggests no testing for duration decisions and advises treatment with expert referral for further decision-making. [1]

Make the planned anticoagulation duration explicit

  • For cerebral venous thrombosis after primary treatment, ASH conditionally suggests testing if anticoagulation would otherwise stop, with indefinite treatment for thrombophilia. If indefinite treatment is already planned, it suggests no testing to guide duration. [1]
  • For splanchnic venous thrombosis in the noncirrhotic decision pathway, the same distinction applies: conditionally test when treatment would otherwise stop and continue indefinitely for thrombophilia; do not test for duration when indefinite therapy is already planned. [1]

Use the familial defect and risk episode to guide selective testing

  • For a minor provoking risk episode in someone with familial VTE and known heterozygous factor V Leiden or prothrombin mutation, ASH suggests no testing for prophylaxis. With familial antithrombin, protein C or protein S deficiency, it suggests selective testing and prophylaxis for carriers. [1]
  • When familial VTE is present but the familial defect is unknown, ASH generally suggests no panel for a minor risk episode. Testing may still be considered with several affected relatives, a young affected relative, patient preference and low testing cost. [1]
  • Without familial VTE, a first-degree relative with antithrombin, protein C or protein S deficiency supports conditional selective testing before a minor risk episode and prophylaxis for carriers. For only a second-degree affected relative, either testing or not testing is reasonable. [1]
  • These minor-risk familial recommendations do not cover homozygous defects or combinations. When a defect is known, selective testing is generally more sensible than expanding to the entire hereditary panel. [1]

Avoid routine testing before contraception or hormone therapy

  • Do not screen the general population for thrombophilia before combined oral contraceptives; this is the guideline’s strong recommendation. For hormone replacement therapy, ASH also suggests no routine testing, but conditionally. [1]
  • With familial VTE but no known familial defect, ASH conditionally suggests no hereditary-thrombophilia panel to guide combined contraceptive or hormone replacement use. [1]
  • With familial VTE and known antithrombin, protein C or protein S deficiency, ASH conditionally suggests selective testing and avoidance of combined oral contraceptives or hormone replacement in carriers. The same testing strategy is not recommended for familial low-risk factor V Leiden or prothrombin mutation. [1]

Preserve relationship-specific pregnancy and cancer criteria

  • For familial VTE with homozygous factor V Leiden, combined factor V Leiden/prothrombin mutation or antithrombin deficiency, ASH conditionally suggests selective testing and antepartum prophylaxis in women carrying the same defect. Homozygous-factor-V-Leiden testing concerns siblings; second-degree family management was not addressed. [1]
  • For familial VTE with protein C or protein S deficiency, ASH allows either selective testing or no testing to guide antepartum prophylaxis. Heterozygous factor V Leiden or prothrombin mutation alone is outside these high-risk pregnancy recommendations. [1]
  • Postpartum testing depends on the familial defect and degree of relationship. Where prophylaxis is indicated under this pathway, continue until 6 weeks after delivery and consider injection burden and patient preferences; use the complete relationship-specific recommendations before prescribing. [1]
  • For ambulatory cancer patients on systemic therapy, without prior VTE, at low or intermediate VTE risk and with a first-degree relative with VTE, ASH conditionally suggests hereditary testing and prophylaxis for carriers. This does not replace separate high-risk cancer prophylaxis guidance. [1]

Limitations and use

  • This summary does not supply anticoagulant selection, doses, laboratory timing around anticoagulation or a complete postpartum family-genotype algorithm.
  • The recommendations address testing strategies, not automatic permission to use hormones after a negative result or an instruction to stop anticoagulation without individualized recurrence and bleeding assessment.
  • Homozygous and combined defects are excluded from several minor-risk and hormone recommendations. Pregnancy scenarios and antiphospholipid-syndrome management need the relevant detailed guidance.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Thrombophilia testing

    Selected recommendation material consulted

Clinical practice guideline

Publication details

Issuing organisation
ASH
Resource type
Clinical practice guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Test only when a defined decision could change
  • Distinguish provoked and unprovoked VTE
  • Make the planned anticoagulation duration explicit
  • Use the familial defect and risk episode to guide selective testing
  • Avoid routine testing before contraception or hormone therapy
  • Preserve relationship-specific pregnancy and cancer criteria
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House